Lozano, Alexander X. http://orcid.org/0000-0001-8424-291X
Chaudhuri, Aadel A. http://orcid.org/0000-0003-3115-3061
Nene, Aishwarya http://orcid.org/0000-0002-5160-5080
Bacchiocchi, Antonietta
Earland, Noah
Vesely, Matthew D. http://orcid.org/0000-0001-9363-945X
Usmani, Abul http://orcid.org/0000-0001-5485-7323
Turner, Brandon E.
Steen, ChloƩ B. http://orcid.org/0000-0001-7290-7128
Luca, Bogdan A.
Badri, Ti http://orcid.org/0000-0002-9869-7541
Gulati, Gunsagar S.
Vahid, Milad R.
Khameneh, Farnaz
Harris, Peter K.
Chen, David Y. http://orcid.org/0000-0002-3681-6576
Dhodapkar, Kavita
Sznol, Mario http://orcid.org/0000-0003-4137-9662
Halaban, Ruth http://orcid.org/0000-0001-8451-1964
Newman, Aaron M. http://orcid.org/0000-0002-1857-8172
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R00CA187192, 1K08CA238711, K08CA237727, R01CA238471, R21CA218950)
Virginia and D.K. Ludwig Fund for Cancer Research
Donald E. and Delia B. Baxter Foundation
Stinehart-Reed FoundationStanford Bio-X Interdisciplinary Initiatives
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
Cancer Research Foundation
V Foundation for Cancer Research
Washington University Alvin J. Siteman Cancer Research Fund
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T35HL007649)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR077926)
Yale Cancer Center
Yale Cancer Center10x Genomics Pilot Program Award
Article History
Received: 14 December 2020
Accepted: 9 November 2021
First Online: 13 January 2022
Competing interests
: A.A.C. has patent filings related to cancer biomarkers and digital cytometry and has served as an advisor/consultant to Roche, AstraZeneca, Daiichi Sankyo, Tempus, Geneoscopy, NuProbe, Fenix Group International and Guidepoint. A.A.C. has stock options in Geneoscopy, research support from Roche and ownership interests in Droplet Biosciences. M.S. has consulted for Idera Pharmaceuticals, Regeneron Pharmaceuticals, Apexigen, Alligator Bioscience, Verastem Oncology, Agenus, Rubius Therapeutics, Bristol Myers Squibb, Genentech-Roche, Boston Pharmaceuticals, Servier Laboratories, Adaptimmune Therapeutics, Immunocore, Dragonfly Therapeutics, Pierre Fabre Pharmaceuticals, Molecular Partners, Boehringer Ingelheim, Innate Pharma, Nektar Therapeutics, Pieris Pharmaceuticals, Numab Therapeutics, Abbvie, Zelluna Immunotherapy, Seattle Genetics/Seagen, Genocea Biosciences, GI Innovation, Chugai-Roche, BioNTech, Eli Lilly, Modulate Therapeutics, Array Biopharma, AstraZeneca and Genmab. M.S. has stock options in EvolveImmune, NextCure, Repertoire Immune Medicines, Adaptive Biotechnologies, Actym Therapeutics and Amphivena Therapeutics and has stock ownership in GlaxoSmithKline and Johnson & Johnson. A.M.N. has patent filings related to expression deconvolution, digital cytometry and cancer biomarkers and has served as an advisor/consultant to Roche, Merck and CiberMed. The other authors declare no conflicts of interest.